Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast689
Helicobacter pylori and gastric cancer: mechanisms and new perspectives348
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects348
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ347
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma340
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC336
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer335
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine307
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence301
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML287
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials284
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice280
Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia275
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial263
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer258
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer230
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation224
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells217
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT215
Targeting GPRC5D for multiple myeloma therapy215
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans211
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis207
Emerging role of RNA sensors in tumor microenvironment and immunotherapy206
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation199
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients198
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency198
Involvement of inflammasomes in tumor microenvironment and tumor therapies180
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study177
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors171
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL167
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leuke167
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders167
Gene and cell therapies in China: booming landscape under dual-track regulation159
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report156
Mesenchymal stem/stromal cells in cancer therapy154
Applications of single-cell sequencing in cancer research: progress and perspectives151
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation151
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation144
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden139
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1139
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial139
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024138
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening134
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018129
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies121
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena120
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting120
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA118
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial118
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia117
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML116
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives109
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms108
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy106
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation104
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium101
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China100
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy99
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential99
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management98
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents97
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis97
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells96
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy94
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients92
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)91
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint89
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy88
Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers88
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy88
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer87
Integrins regulate stemness in solid tumor: an emerging therapeutic target86
A four-stage model for murine natural killer cell development in vivo86
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma85
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma85
Metabolic reprogramming in the tumor microenvironment of liver cancer83
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia82
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients82
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma81
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies81
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma81
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation81
0.052886009216309